The factors associated with co-trimoxazole hypersensitivity in people living with HIV/AIDS: a retrospective study
DOI:
https://doi.org/10.18203/2349-3933.ijam20204527Keywords:
People living with HIV/AIDS, Co-trimoxazole, Hypersensitivity, Associated factorsAbstract
Background: Antibiotic adverse drug reactions (ADRs) can occurred during any treatment of infection, especially opportunistic infections in people living with HIV/AIDS (PLWHA). Co-trimoxazole is a sulfonamide fixed dose combination antibiotic, consisted of sulfamethoxazole and trimethoprim which is effective in treatment of several infections and for prophylaxis of pneumocystis jiroveci pneumonia. The universal use of co-trimoxazole for prophylaxis has been shown to decrease hospitalizations, morbidity and mortality among PLWHA, but potentially associated with ADRs include drug hypersensitivity reaction. The objective was to identify factors associated with co-trimoxazole hypersensitivity in PLWHA.
Methods: A retrospective study were enrolled 404 participants PLWHA who were received co-trimoxazole due to co-trimoxazole prophylaxis therapy (CPT), between January 2015–December 2018. The independence variables such as age, sex, history of allergy, hypersensitivity reactions, duration of therapy (days), CD4 (cells/µl) and opportunistic infection to co-trimoxazole hypersensitivity reaction were analyzed using spearman test.
Results: Mostly of the participants was male: 253 (62.60%). Eighteen (4.50%) with history of allergy, 64 (15.90%) were known co-trimoxazole hypersensitivity reaction. The most frequent clinical manifestation was maculopapular rash: 27 (42.3%), followed by urticaria alone: 17 (26.3%), fixed drug eruption: 12 (19.6%), and angioedema with or without urticaria: 8 (11.8%). The history of allergy, opportunistic infection and duration of treatment were associated factors to co-trimoxazole hypersensitivity reaction.
Conclusions: This study was identified, that history of allergy, duration of treatment and opportunistic infection were factors associated with co-trimoxazole hypersensitivity in PLWHA.
References
Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for prediction of co-trimoxazole induced severe cutaneous reactions. Pharmacogenet Genom.2015;25:402-11.
Denue BA. Knowledge regarding co-trimoxazole preventive therapy among patients who are HIV positive in a tertiary health facility, northeastern Nigeria. Sub-Saharan Afr J Med. 2018;4:31-6.
Raizada N, Chauhan LS, Babu S, Thakur R, Khera A, Wares F, et al. Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India. Plos One. 2009;4(6):1-7.
Chantachaeng W, Chularojanamontri L, Kulthanan K, Jongjareamprasert K, Dhana N. Cutaneous adverse reactions to sulfonamide antibiotics. Asian Pac J Allergy Immunol. 2011;29:284-9.
Daftarian MP, Filion LG, Cameron W, Conway B, Roy R, Tropper F, et al. Immune response to sulfamethoxazole in patients with AIDS. Clinic Diagn Laborat Immunol. 1995;2(3):199-204.
Suthar AB, Granich R, Mermin J, Riea AV. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 2012;90:128–38C.
7. Diriba L, Pharm B, Worku F, Girma T. Evaluation of prophylactic use of cotrimoxazole for people living with HIV/AIDS in Jimma university specialized hospital, Southwest Ethiophia. Ethiop J Health Sci. 2008;18(3):59-64.
Hasse B, Walker S, Fehr J, Furrer H, Hoffmann M, Battegay M, et al. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV cohort study. Antimicrob Age Chemoth. 2014;58(4):2363-8.
Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lanc. 2004; 364:1865-71.
Denegetu AW, Dolamo BL. HIV screening among TB patients and co-trimoxazole preventive therapy for TB/HIV patients in Addis Ababa: facility based descriptive study. Plos One. 2014;9(2):1-7.
Watera C, Todd J, Muwonge R, Whitworth J, Miiro JN, Brink A, et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1 infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr. 2006;42(3):373-8.
Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol. 2008;121(4):826-32.
Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of Cross-Reactivity between Sulfonamide Antibiotics and Sulfonamide Nonantibiotics. N Engl J Med. 2003;349:1628-35.
Schnyder B, Pichler WJ. Allergy to sulfonamides. J Allergy Clin Immunol. 2013;131(1):256-7.
Ku SW, Jiamsakul A, Joshi L, Pasayan MKU, Widhani A, Chaiwarith R, et al. Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV. J Int AIDS Soc. 2019;22:e25264.
Masters PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2003;163:402-10.
Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d’Ivoire: a randomised trial. Lanc. 1999;35:1463-8.
Kassie GM, Duga AL, Nebi PJ. Evaluation of co-trimoxazole as preventive therapy for people living with HIV/AIDS in Jimma health center, Southwest Ethiopia. Int Res J Pharm. 2014;5(5):403-6
Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, Otieno K. Does Cotrimoxazole Prophylaxis for the Prevention of HIV-Associated Opportunistic Infections Select for Resistant Pathogens in Kenyan Adults? Am. J. Trop. Med. Hyg. 2008;79(3):320-30.
Polyak CS, Yuhas K, Singa B, Khaemba M, Walson J, Richardson BA, et al. Cotrimoxazole prophylaxis discontinuation among antiretroviral treated HIV 1 infected adults in Kenya: a randomized non-inferiority trial. Plos Med. 2016;13(1):1-16.
Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Brit J Pharmacol. 2001;133:295-305.
Thong BY. Update on the management of antibiotic allergy. Allergy Ashtma Immunol Res. 2010;2(2):77-86.
Burkhart C, Greyerz SV, Depta JPH, Naisbitt DJ, Britschgi M, Park KB. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Brit J Pharmacol. 2001;132:623-30.
Yunihastuti E, Widhani A, Karjadi TH. Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. Asia Pac Allergy. 2014;4:54-67.
Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients. A Meta-analysis of Prospective Studies. J Americ Medic Assoc. 1998;279(15):1200-5.
Macy E, Romano A, Khan D. Practical Management of Antibiotic Hypersensitivity in 2017. Clinic Managem Revi. 2017;577-86.
Pichler WJ, Srinoulprasert Y, Yun J, Hausmann O. Multiple Drug Hypersensitivity. Int Arch Allergy Immunol. 2017;129-38.
Legendre DP, Muzny CA, Marshall GD, Swiatlo E. Antibiotic Hypersensitivity Reactions and Approaches to Desensitization. Clinic Infect Diseas. 2014;58:1140-7.
Borges MS, Thong B, Blanca M, Ensina LFC, Diaz SG, Greenberger PA, et al. Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. Worl Allerg Organizat J. 2013;6:1-23.
